Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Managing problem gout

A G Fam1

  • 1Division of Rheumatology, Sunnybrook Health Science Centre, University of Toronto, Canada.

Annals of the Academy of Medicine, Singapore
|May 20, 1998
PubMed
Summary
This summary is machine-generated.

Non-steroidal anti-inflammatory drugs (NSAIDs) are primary for acute gout. Allopurinol is preferred for chronic gout and hyperuricemia, with dose adjustments for specific patient groups.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Acute calcium pyrophosphate dihydrate crystal-induced tenosynovitis.

Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases·2008
Same author

Current therapy of acute microcrystalline arthritis and the role of corticosteroids.

Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases·2008
Same author

Recent advances in the management of adult myositis.

Expert opinion on investigational drugs·2002
Same author

Cholesterol crystals in gouty bursitis.

The Journal of rheumatology·2001
Same author

Difficult gout and new approaches for control of hyperuricemia in the allopurinol-allergic patient.

Current rheumatology reports·2001
Same author

Efficacy and safety of desensitization to allopurinol following cutaneous reactions.

Arthritis and rheumatism·2001
Same journal

"Gazing into the crystal ball of mortality prediction in conservative kidney care": Correspondence.

Annals of the Academy of Medicine, Singapore·2026
Same journal

Vascular stiffness and sepsis mortality: A promising signal in search of clinical relevance.

Annals of the Academy of Medicine, Singapore·2026
Same journal

Transcatheter aortic valve implantation for severe aortic regurgitation with Trilogy system: Initial Southeast Asia experience.

Annals of the Academy of Medicine, Singapore·2026
Same journal

Singapore expert consensus on optimising lipid-lowering strategies in acute coronary syndrome: A modified Delphi study.

Annals of the Academy of Medicine, Singapore·2026
Same journal

Association of estimated pulse wave velocity with 28-day mortality in sepsis: A MIMIC-IV study.

Annals of the Academy of Medicine, Singapore·2026
Same journal

Prognostic value of the monocyte-to-albumin ratio in nasopharyngeal carcinoma: A retrospective cohort study.

Annals of the Academy of Medicine, Singapore·2026
See all related articles

Area of Science:

  • Rheumatology
  • Pharmacology

Background:

  • Gout management involves acute and chronic treatment strategies.
  • Traditional treatments like NSAIDs and colchicine have limitations.

Purpose of the Study:

  • To review current therapeutic options for gout management.
  • To highlight appropriate drug choices based on patient profiles and disease presentation.

Main Methods:

  • Review of pharmacological agents for gout treatment.
  • Analysis of drug efficacy, adverse reactions, and contraindications.

Main Results:

  • NSAIDs are first-line for acute gout.
  • Corticosteroids offer alternatives for specific patient groups.
  • Allopurinol is the preferred agent for hyperuricemia and chronic gout.

Related Experiment Videos

  • Dose adjustments for allopurinol are crucial in elderly, renal impairment, and transplant patients.
  • Uricosuric drugs have limited use but are valuable in specific cases, such as allopurinol allergy.

    • Conclusions:

    • Optimal gout management requires individualized treatment selection.
    • Careful consideration of patient comorbidities and drug-specific profiles is essential for effective therapy.